

# Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer 18F-FDG PET Radiomics

Guilherme Kolinger, David Vállez García, Gerbrand Maria Kramer, Virginie Frings, Gerben J.C. Zwezerijnen, Egbert Smit, Adrianus Johannes de Langen, Irène Buvat, Ronald Boellaard

# ▶ To cite this version:

Guilherme Kolinger, David Vállez García, Gerbrand Maria Kramer, Virginie Frings, Gerben J.C. Zwezerijnen, et al.. Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer 18F-FDG PET Radiomics. Journal of Nuclear Medicine, 2022, 63 (6), pp.919-924. 10.2967/jnumed.121.262660 . inserm-03872933

# HAL Id: inserm-03872933 https://inserm.hal.science/inserm-03872933

Submitted on 26 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title: Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer 18F-FDG PET Radiomics

Running title: Effects of time on NSCLC PET radiomics

Authors: Guilherme D. Kolinger<sup>1</sup>, David Vállez García<sup>1,2</sup>, Gerbrand Maria Kramer<sup>2</sup>, Virginie Frings<sup>2</sup>,

Gerben J.C. Zwezerijnen<sup>2</sup>, Egbert F. Smit<sup>3,4</sup>, Adrianus Johannes de Langen<sup>4</sup>, Irène Buvat<sup>5</sup>, and Ronald

Boellaard<sup>1,2</sup>

<sup>1</sup>Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The

Netherlands

<sup>2</sup>Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, location VU Medical

Center, Amsterdam, The Netherlands

<sup>3</sup>Department of Pulmonology, Amsterdam University Medical Center, location VU Medical Center, Amsterdam,

The Netherlands

<sup>4</sup>Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>5</sup>Laboratoire d'Imagerie Translationnelle en Oncologie, INSERM, Institut Curie, Université Paris-Saclay, Orsay,

France

**Disclaimer:** IB is involved in the development of LIFEx. No other potential conflicts of interest

relevant to this article exist.

Corresponding author: Guilherme D. Kolinger (ORCID ID: 0000-0001-9505-4869)

**Address:** 

Medical Imaging Center

University Medical Center Groningen

Hanzeplein 1, 9713GZ, Groningen

The Netherlands.

Telephone: 0031 50 3610320

1

E-mail: g.domingues.kolinger@umcg.nl

First author in training (PhD candidate)

Financial Disclosure: This project has received funding from the European Union's Horizon 2020

research and innovation programme under the Marie Skłodowska-Curie [grant agreement No 764458].

Word count: 4993

#### **ABSTRACT**

Positron emission tomography (PET) radiomics applied to oncology allows the measurement of intratumoral heterogeneity. This quantification can be affected by image protocols hence there is an increased interest in understanding how radiomic expression on PET images is affected by different imaging conditions. To address that, this study explores how radiomic features are affected by changes in <sup>18</sup>F-FDG uptake time, image reconstruction, lesion delineation, and radiomics binning settings. Methods: Ten non-small cell lung cancer (NSCLC) patients underwent <sup>18</sup>F-FDG PET scans on two consecutive days. On each day, scans were obtained at 60min and 90min post-injection and reconstructed following EARL version 1 (EARL1) and with point-spread-function resolution modelling (PSF-EARL2). Lesions were delineated using thresholds at SUV=4.0, 40% of SUV<sub>max</sub>, and with a contrast-based isocontour. PET image intensity was discretized with both fixed bin width (FBW) and fixed bin number (FBN) before the calculation of the radiomic features. Repeatability of features was measured with intraclass correlation (ICC), and the change in feature value over time was calculated as a function of its repeatability. Features were then classified on use-case scenarios based on their repeatability and susceptibility to tracer uptake time. Results: With PSF-EARL2 reconstruction, 40% of SUV<sub>max</sub> lesion delineation, and FBW intensity discretization, most features (94%) were repeatable at both uptake times (ICC>0.9), 39% being classified for dual-time-point use-case for being sensitive to changes in uptake time, 39% were classified for cross-sectional studies with unclear dependency on time, 20% classified for cross-sectional use while being robust to tracer uptake time changes, and 6% were discarded for poor repeatability. EARL1 images had one less repeatable feature than PSF-EARL2 (Neighborhood Gray-Level Different Matrix Coarseness), the contrast-based delineation had the poorest repeatability of the delineation methods with 45% features being discarded, and FBN resulted in lower repeatability than FBW (45% and 6% features were discarded, respectively). Conclusion: Repeatability was maximized with PSF-EARL2 reconstruction, lesion delineation at 40% of SUV<sub>max</sub>, and FBW intensity discretization. Based on their susceptibility to tracer uptake time, radiomic features were classified into specific NSCLC PET radiomics use-cases.

**Key words:** PET; Radiomics; Texture analysis; Repeatability; Dual-Time-Point

#### INTRODUCTION

 $^{18}$ F-2-Fluoro-2-deoxy-2-D-glucose ( $^{18}$ F-FDG) positron emission tomography/computed tomography (PET/CT) is an important technique for staging and treatment response evaluation of patients with non-small cell lung cancer (NSCLC). This evaluation can be achieved either visually or using standardized uptake values (SUV) and total lesion glycolysis measurements (I–5). However, these semi-quantitative approaches ignore possible tracer uptake heterogeneity within the tumor (6), overlooking potentially useful information. To address that, the field of *radiomics* measures textural information available in medical images, resulting in a more complete phenotyping of the tumor (7–9).

PET radiomics in oncology allows the extraction of several features characterizing tumor tracer uptake, shape, and intra-tumoral heterogeneity (10-13). This approach showed promising results, including lesion histological sub-type identification, aiding automated lesion delineation, and disease-free survival prediction (14-18). However, radiomic features are sensitive to several image settings, including PET acquisition and reconstruction, image noise, lesion segmentation method, and signal intensity discretization (11,19-26). This leads to difficulties in multi-center studies, possibly explaining the poor reproducibility of results that has raised skepticism on the usefulness of radiomics (9,19,27-31). Furthermore, these issues are amplified by the lack of negative publications on the field (32). Strategies have been developed to mitigate this variability, improving post-reconstruction harmonization of textural features (33-35).

One aspect of <sup>18</sup>F-FDG PET radiomics that has not been extensively explored is its uptake time dependence. The time between tracer injection and image acquisition alters the uptake in metabolically active regions where <sup>18</sup>F-FDG gradually accumulates, affecting SUV-related metrics and their repeatability (36–38). <sup>18</sup>F-FDG PET/CT textural analysis from dual-time-point static scans has been used to differentiate benign and malignant pulmonary lesions despite features presenting a wide range of accuracy (39,40). Time-related PET radiomics have been also explored as *dynamic features* (41). However, neither of these studies assessed how tracer uptake time could influence textural features repeatability.

Our hypothesis is that different features have different dependence on tracer uptake time and that this dependence may be influenced by image settings. Therefore, we evaluate how radiomic features (SUV-based and textural) are affected by tracer uptake time and whether its effects are smaller or larger than feature repeatability. Based on each feature's repeatability and dependence on tracer uptake time, features are classified for cross-sectional or single-injection dual-time-point use-cases. Several image settings are considered, including PET/CT image reconstruction algorithms, lesion delineation methods, and intensity discretization strategies.

#### MATERIALS AND METHODS

#### **Dataset**

Ten patients with confirmed stage IIIB or IV NSCLC underwent double baseline <sup>18</sup>F-FDG PET/CT scans on a Gemini TF scanner (Philips Healthcare, Cleveland, OH, USA), as previously described (*5,20*). Patients fasted for six hours or more, then a low-dose CT was acquired for attenuation correction followed by a whole-body <sup>18</sup>F-FDG PET scan 60 min after tracer injection. Thirty minutes later, a second whole-body PET and low-dose CT were performed. This procedure was repeated within three days of the first scan for test-retest measurements. All PET data were normalized and corrected for scatter and random events, dead time, attenuation, and decay. Two reconstruction protocols were used, one following the EARL version 1 guidelines (EARL1) and another with point-spread-function resolution modelling (PSF-EARL2) (*42–44*). PET images had a final resolution of 144×144×254 with a voxel size of 4×4×4mm³. On the first day of scans, the average injected activity was 248MBq (range: 194–377MBq) and was 238MBq (192–392MBq) on the second day. The average post-injection start times on the first day were 61min (59–67min) and 92min (90–97min), and 60min (60–63min) and 90min (90–95min) on the second day. All patients gave written informed consent before enrolment and the study was approved by the Medical Ethics Review Committee of the VU University Medical Center (Dutch trial register [trialregister.nl] NTR3508).

#### **Radiomic Feature Extraction**

Lesion delineation and radiomic feature extraction were performed using LIFEx (version 6.30) (45). All lesions were included for the analysis, namely the primary and metastatic lesions (intra- and extra-thoracic), yielding 1 to 10 lesions as a function of the patient. Lesions were delineated on the PSF-EARL2 PET images using an isocontour at 40% of each lesion's SUV<sub>max</sub>, then radiomic features were extracted with intensity discretization using a fixed bin width (FBW) of 0.25g/mL ranging from 0–60g/mL of each lesion (the 60g/mL upper bound was higher than the SUV<sub>max</sub> of all lesions). This combination of image and processing settings was considered the reference settings for radiomic analysis as they were previously shown to optimize test-retest (19,36,46). Other image settings were explored, including lesion delineation and feature extraction from EARL1 images, lesion delineations with a fixed isocontour at an SUV threshold of 4.0 (SUV4) and a contrast-based isocontour at 0.5×SUV<sub>peak</sub> + SUV<sub>background</sub> (Contrast; SUV<sub>background</sub> was the mean uptake in a shell located 2cm away from the volume defined at 70% of SUV<sub>max</sub>, excluding voxels with SUV>4), and intensity discretization with a fixed bin number (FBN) of 64 bins in a variable range of SUV<sub>min</sub>-SUV<sub>max</sub>.

In total, 49 radiomic features from seven classes were extracted (full list given in Supplemental Table 1): six conventional PET metrics (*Conventional*), five shape-based (*Shape*), six histogram-based (*Histogram*), seven grey-level co-occurrence matrix (*GLCM*), eleven grey-level run-length matrix (*GLRLM*), eleven grey-level zone-length matrix (*GLZLM*), and three neighborhood grey-level difference matrix (*NGLDM*). Features were obtained only for lesions that included at least 64 voxels. LIFEx's feature definition follows the IBSI standard results (*47,48*).

### **Data Analysis**

Features calculated from images obtained at different time-points on the first day of scans were statistically compared using pairwise Wilcoxon signed-rank tests. P-values below 0.05 were considered statistically significant after Benjamini-Hochberg false discovery rate correction. Change in feature

value was measured as a function of tracer uptake time by using its test-retest at 60min p.i. as baseline (analogous to a Z-score):

$$Z = \frac{(RF_{90} - RF_{60}) - mean(TRT_{60})}{sd(TRT_{60})}$$

RF<sub>60</sub> and RF<sub>90</sub> represent the radiomic feature values at 60min and 90min p.i., respectively. TRT<sub>60</sub> is the test-retest difference between the feature values at the second- and first-day scans (at 60min p.i.). Therefore, the effects of tracer uptake time on radiomic features were contextualized with respect to its repeatability: Z-scores lower than 1 indicate changes with uptake time smaller than test-retest variability and Z-scores higher than 1 show a change larger than their repeatability.

A feature was considered repeatable if the intraclass correlation coefficient (ICC; agreement type, two-way mixed-effects model, single rating) between test-retest scans (same reconstruction, delineation method and discretization) was higher than 0.9 at both time-points. A feature was defined as robust against change in tracer uptake time if it was not significantly affected by tracer uptake time after false discovery rate correction and if its value changed from 60-min to 90-min less than it changed from one day to another (i.e. mean Z-score < 1). Finally, features were assigned to a use-case based on their repeatability and susceptibility to tracer uptake time (Figure 1): features that were repeatable and susceptible to tracer uptake time were classified for *Dual-Time-Point* (DTP) studies; repeatable features with uncertain response to tracer uptake time were classified as *Cross-Sectional level 1* (CS1); repeatable features that were robust to tracer uptake time were classified as *Cross-Sectional level 2* (CS2); features with poor repeatability at any time-point were *Discarded*. Statistical analysis was carried using R version 4.0.4.

### **RESULTS**

## Feature Dependence on Uptake Time

All *Conventional* features were significantly affected by tracer uptake interval and increased in value with increased uptake time (Figure 2, positive mean Z-score). *Shape* features were not

significantly different between the two tracer uptake times. Half of the *Histogram* features were affected by uptake time (note that *Histogram Entropy log10* and *Histogram Entropy log2* are equivalent after re-scaling with Z-scores). 4/7 *GLCM* features significantly increased over time and only one decreased. One *GLRLM*, two *GLZLM* and two *NGLDM* features were not statistically significantly dependent on tracer uptake time (Figure 2). The features of each class with the highest Z-score and statistically significant dependent on tracer uptake time were (p<0.05) *Conventional SUV*<sub>mean</sub> (average Z-score and standard deviation=1.36±0.98), *Histogram Entropy* (1.04±0.73), *GLCM Dissimilarity* (1.35±1.29), *GLRLM LRHGE* (1.38±1.69), *GLZLM SZLGE* (-1.24±1.86), and *NGLDM Contrast* (1.28±2.10).

#### **Radiomic Feature Use-Case Classification**

94% (46/49) of the features had reliable repeatability (ICC>0.9, Supplemental Figure 1). In total, 35% (17/49) of features were classified as DTP, 39% (19/49) as CS1, 20% (10/49) as CS2, and 6% (3/49) were discarded (Supplemental Figure 1). No *Conventional* feature was classified for CS2 use-case, no *Shape* feature was classified for dual-time-point use, and no *NGLDM* feature was classified for CS1. The remaining feature classes had mixed use-case classification (Figure 3).

## Influence of Image Settings on Repeatability and Use-Case Classification

The reference settings (PSF-EARL2 reconstruction, 40% of SUV<sub>max</sub> delineation and fixed bin width discretization) had less discarded features than other image settings (Figure 4). With EARL1 (and recommended delineation and discretization), images had one less repeatable feature (*NGLDM Coarseness*) than PSF-EARL2 (Figure 4). With PSF-EARL2 and fixed bin width discretization, the Contrast-based lesion delineation method had poorer repeatability than the other methods and SUV4 had fewer repeatable features than 40% of SUV<sub>max</sub> (22, 6, and 3 features discarded, respectively). Lastly, FBN had considerably lower repeatability than FBW (22 and 3 discarded features with recommended reconstruction and delineation, respectively; Supplemental Figure 2).

Using the reference delineation and discretization, EARL1 had no *Conventional* feature classified for dual-time-point use-case (Figure 4; Supplemental Figure 3). *Histogram* features were only classified for CS1 use-case (or were discarded) while all *Shape* features were classified for CS2. In total, 8% (4/49) features had dual-time-point classification, 67% (33/49) had CS1, 16% (8/49) had CS2, and 8% (4/49) were discarded with EARL1 reconstruction when using the reference delineation and discretization.

Despite using the reference reconstruction and discretization, the contrast-based approach resulted in 45% (22/49) of features being discarded (Figure 4; Supplemental Figure 3). With SUV4, 12% (6/49) features were discarded, and all repeatable *Conventional* features had dual-time-point classification; other feature classes had mixed use-case classifications.

Using FBN for discretization resulted in different use-case classifications as compared to FBW, even when both used the reference reconstruction and delineation methods (Figure 4). The exceptions to that were the *Conventional* and *Shape* features since those are not dependent on the image intensity discretization (Supplemental Figure 3). With PSF-EARL2, 40% of SUV<sub>max</sub> and a fixed bin number, only one grey-level-based feature was classified for CS1: *GLRLM RLNU*. Furthermore, all *GLCM* and *NGLDM* features were robust to tracer uptake time with a fixed bin number discretization (CS2 usecase) and all *Histogram* features were Discarded (Figure 4).

#### **DISCUSSION**

This study demonstrated that for PET image reconstructed with PSF-EARL2, lesion delineation with 40% of SUV<sub>max</sub> and intensity discretization using fixed bin width, most (94%) traditional and grey-level-based features were repeatable at both 60 min and 90 min p.i. scans. From the radiomic features assessed, 35% were repeatable and able to detect a change as a function of uptake time (DTP), 39% were repeatable but had an unclear dependency on uptake time (CS1), 20% were repeatable and robust against tracer uptake time changes (CS2), and 6% were not repeatable (Discarded). Additionally, analyses performed on PET images reconstructed using EARL1, lesion delineation using a contrast-

based approach or a fixed threshold method, and intensity discretization using a fixed number of bins decreased repeatability and led to different use-case classification of radiomic features.

Overall, more features significantly increased (22/49) with time than decreased (12/49), as found previously (49). Conventional features increased over time, as expected (50,51), and Shape features slightly decreased in the delayed PET scan. This decrease in volume due to a higher threshold for lesion delineation (at 40% of SUV<sub>max</sub>) agrees with the lower metabolic tumor volume of breast cancer for delayed PET scans (52). The statistically significant Histogram features affected by tracer uptake time were Energy (decreased) and Entropy (increased). The first is related to the uniformity of the distribution and the second to its randomness, therefore reflecting an increase in tumor heterogeneity at delayed <sup>18</sup>F-FDG PET scans (52). Yet, these features were not significantly affected by uptake time on peripheral nerve sheath tumors with relatively low <sup>18</sup>F-FDG uptake (49), emphasizing that translation of radiomic results between different tumor types must be carried with caution even with first-order features.

The increase of *GLRLM RP*, *GLZLM ZP*, and *NGLDM Contrast* over time reflects an increased heterogeneity, as *RP* and *ZP* are low for highly uniform VOIs (47) and *Contrast* is related to the intensity difference between neighboring regions. However, there was a decrease in *GLRLM* and *GLZLM non-uniformity*, which suggests a reduction in heterogeneity over time. These non-uniformity features have been previously reported as being dependent on time (49,52), but with a small effect size and a direction of change that was not uniform across studies. Therefore, more features suggest an increase in tumor heterogeneity over time than decrease, agreeing with previous findings for advanced breast cancer (52) but disagreeing with peripheral nerve sheath tumors results (49). This incompatibility may come from the tracer uptake levels in the tumors. The present study and Garcia-Vicente et al. (52) assessed tumor with relatively high <sup>18</sup>F-FDG uptake and found increasing heterogeneity over time, while Lovat et al. (49) studied low tracer uptake lesions.

Radiomic features classified for CS1 use-case were repeatable at both tracer uptake times but did not have any clear relationship with tracer uptake time, i.e., were neither robust nor sensitive. These features may be suitable for cross-sectional studies if all images are acquired with similar post-injection

times. The dependence of the CS1 features on time could explain some of their variability and range previously found on lung cancer assessment (15,25,46). Other repeatable features were robust against changes in tracer uptake time (CS2) and are recommended for studies with inconsistent post-injection scanning time. In contrast, repeatable features statistically significantly and substantially affected by tracer uptake time were classified for dual-time-point use-case. Like CS1 features, dual-time-point features may be used on images acquired with similar tracer uptake time (e.g., SUV<sub>mean</sub>), but can also measure the effect of time on feature values. Previous studies have reported a possible added benefit of a dual-time-point scanning protocol for differentiation between benign and malignant pulmonary lesions with textural features (39,40) and for breast cancer intra-tumoral heterogeneity assessment (52). Unfortunately, given the different nature of the lesions and analysis settings in those previous studies, it is not possible to directly compare the radiomic features found useful by these authors with the ones we identified as appropriate for dual-time-point studies.

As shown previously (19), EARL1 reconstructions resulted in worse repeatability than PSF-EARL2. Additionally, PSF-EARL2 reconstructions also display higher heterogeneity (20) and are recommended for textural analysis. Concerning the lesion delineation method, a fixed isocontour lesion delineation (SUV4) yielded poorer repeatability than an adaptive threshold based on 40% of SUV<sub>max</sub> as expected from the literature (36). The contrast-based delineation had the poorest repeatability of all methods and is thus not recommended for radiomics. Furthermore, previous findings that an FBW intensity discretization has a superior repeatability for PET radiomics than FBN were reproduced (19,46,47). For historical cohorts where only EARL1 reconstruction is available, few features are viable for dual-time-point studies (Figure 4). With lesion delineation at 40% of SUV<sub>max</sub> and discretization with FBW, EARL1 protocol still provides several repeatable radiomic features.

The analysis of data from a single scanner vendor and the inclusion of a single tumor type (NSCLC, including intra- and extra-thoracic lesions), especially given that features have different expression for different cancer types, are some limitations of our study and multi-center studies are needed to verify our findings. Furthermore, lesion delineation is affected by differences in voxel size, which impacts radiomic feature values, but not necessarily the use-case classification of features,

although this would need to be explored. Data from static scans 30min apart was evaluated. Nevertheless, it is possible that additional radiomic information could be obtained from scans acquired further apart in uptake time. Finally, several features were analyzed under different image conditions on only 10 subjects. This study may thus be subject to type 1 errors although a false discovery rate correction was applied to the statistical analysis.

In summary, EARL1 reconstruction led to fewer features being classified for dual-time-point use-case than PSF-EARL2. Textural features were not robust against changes in tracer uptake interval when SUV4 was used for lesion delineation, showing that for NSCLC radiomics, this method should only be applied to PET images acquired with a similar uptake time. Furthermore, most features were discarded when using the contrast-based delineation method or the FBN intensity discretization and their use is not recommended for NSCLC <sup>18</sup>F-FDG PET radiomic studies.

#### **CONCLUSION**

This study demonstrated that PET radiomics can be repeatable, summarized the features' susceptibility to post-injection PET scanning time, and classified the features into reliable use-cases for NSCLC radiomics: dual-time-point and cross-sectional studies. Repeatability and use-case of radiomic features depended on PET image reconstruction, lesion delineation and intensity discretization, and recommendations were provided accordingly.

## **KEY POINTS**

Question: Is the change of radiomic features with <sup>18</sup>F-FDG uptake time larger than their repeatability and can that be used for temporal textural analysis?

Pertinent findings: PET image reconstruction with PSF modelling, lesion delineation at 40% of SUVmax and intensity discretization with fixed bin width resulted in repeatable radiomic features at

60min and 90min post-injection scans and provided reliable information for cross-sectional and dual-time-point studies.

Implications for patient care: Radiomic features were identified and classified for potential use-cases in cross-sectional and dual-time-point protocols, providing reliable information about tumor heterogeneity for non-small cell lung cancer assessment.

## REFERENCES

- Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. *Nucl Med Biol*. 2000;27:647-655.
- Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F] 2-fluoro-2-deoxy-d-glucose and positron emission tomography: An overview of different analytical methods. *Eur J Nucl Med Mol Imaging*. 2000;27:731-743.
- 3. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in Oncology. *J Nucl Med*. 2008;49:480-508.
- 4. Toma-Dasu I, Uhrdin J, Lazzeroni M, et al. Evaluating tumor response of non-small cell lung cancer patients with 18F-Fludeoxyglucose Positron Emission Tomography: Potential for treatment individualization. *Int J Radiat Oncol Biol Phys.* 2015;91:376-384.
- 5. Kramer GM, Frings V, Hoetjes N, et al. Repeatability of quantitative whole-body 18F-FDG PET/CT uptake measures as function of uptake interval and lesion selection in non-small cell lung cancer patients. *J Nucl Med*. 2016;57:1343-1349.
- O'Connor JPB, Rose CJ, Waterton JC, Carano RAD, Parker GJM, Jackson A. Imaging intratumor heterogeneity: Role in therapy response, resistance, and clinical outcome. *Clin Cancer Res*. 2015;21:249-257.

- 7. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data.

  \*\*Radiology. 2015;278:563-577.
- 8. Zwanenburg A. Radiomics in nuclear medicine: Robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. *Eur J Nucl Med Mol Imaging*. 2019;46:2638-2655.
- 9. Liu Z, Wang S, Dong D, et al. The applications of radiomics in precision diagnosis and treatment of Oncology: opportunities and challenges. *Theranostics*. 2019;9:1303-1322.
- 10. Buvat I, Orlhac F, Soussan M. Tumor texture analysis in PET: Where do we stand? *J Nucl Med*. 2015;56:1642-1644.
- 11. Ha S, Choi H, Paeng JC, Cheon GJ. Radiomics in Oncological PET/CT: A methodological overview.

  Nucl Med Mol Imaging. 2019;53:14-29.
- 12. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: Extracting more information from medical images using advanced feature analysis. *Eur J Cancer*. 2012;48:441-446.
- 13. Orlhac F, Soussan M, Maisonobe J-A, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: Relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. *J Nucl Med*. 2014;55:414-422.
- 14. Pfaehler E, Mesotten L, Kramer G, et al. Textural feature based segmentation: a repeatable and accurate segmentation approach for tumors in PET Images. In: Papież BW, Namburete AIL, Yaqub M, Noble JA, eds. *Med Image Underst Anal*. 2020:3-14.
- 15. Mattonen SA, Davidzon GA, Benson J, et al. Bone marrow and tumor radiomics at 18F-FDG PET/CT: impact on outcome prediction in non–small cell lung cancer. *Radiology*. 2019;293:451-459.

- Lee JW, Lee SM. Radiomics in Oncological PET/CT: Clinical applications. *Nucl Med Mol Imaging*.
   2018;52:170-189.
- 17. Kirienko M, Cozzi L, Rossi A, et al. Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions. *Eur J Nucl Med Mol Imaging*. 2018;45:1649-1660.
- 18. Kirienko M, Cozzi L, Antunovic L, et al. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. *Eur J Nucl Med Mol Imaging*. 2018;45:207-217.
- 19. Pfaehler E, Beukinga RJ, de Jong JR, et al. Repeatability of 18 F-FDG PET radiomic features: A phantom study to explore sensitivity to image reconstruction settings, noise, and delineation method. *Med Phys.* 2019;46:665-678.
- van Velden FHP, Kramer GM, Frings V, et al. Repeatability of radiomic features in non-small-cell lung cancer [18F]FDG-PET/CT Studies: Impact of reconstruction and delineation. *Mol Imaging Biol.* 2016;18:788-795.
- 21. Shiri I, Rahmim A, Ghaffarian P, Geramifar P, Abdollahi H, Bitarafan-Rajabi A. The impact of image reconstruction settings on 18F-FDG PET radiomic features: Multi-scanner phantom and patient studies. *Eur Radiol*. 2017;27:4498-4509.
- 22. Reynés-Llompart G, Sabaté-Llobera A, Llinares-Tello E, Martí-Climent JM, Gámez-Cenzano C. Image quality evaluation in a modern PET system: Impact of new reconstructions methods and a radiomics approach. *Sci Rep.* 2019;9:1-9.
- 23. Ketabi A, Ghafarian P, Mosleh-Shirazi MA, Mahdavi SR, Rahmim A, Ay MR. Impact of image reconstruction methods on quantitative accuracy and variability of FDG-PET volumetric and textural measures in solid tumors. *Eur Radiol*. 2019;29:2146-2156.

- 24. Yan J, Chu-Shern JL, Loi HY, et al. Impact of image reconstruction settings on texture features in 18F-FDG PET. *J Nucl Med*. 2015;56:1667-1673.
- 25. Bashir U, Azad G, Siddique MM, et al. The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. *EJNMMI Res*. 2017;7:1-9.
- 26. Leijenaar RTH, Nalbantov G, Carvalho S, et al. The effect of SUV discretization in quantitative FDG-PET Radiomics: The need for standardized methodology in tumor texture analysis. *Sci Rep*. 2015;5:1-10.
- 27. Pfaehler E, van Sluis J, Merema BBJ, et al. Experimental multicenter and multivendor evaluation of PET radiomic features performance using 3D printed phantom inserts. *J Nucl Med*. 2020:61:469-476.
- 28. Hatt M, Lucia F, Schick U, Visvikis D. Multicentric validation of radiomics findings: Challenges and opportunities. *EBioMedicine*. 2019;47:20-21.
- 29. Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: A systematic review. *Int J Radiat Oncol Biol Phys.* 2018;102:1143-1158.
- 30. Desseroit M-C, Tixier F, Weber WA, et al. Reliability of PET/CT shape and heterogeneity features in functional and morphologic components of non-small cell lung cancer tumors: A repeatability analysis in a prospective multicenter cohort. *J Nucl Med*. 2017;58:406-411.
- 31. Konert T, Everitt S, Fontaine MDL, et al. Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any? *PLOS ONE*. 2020;15:e0228793.

- 32. Buvat I, Orlhac F. The dark side of radiomics: On the paramount importance of publishing negative results. *J Nucl Med.* 2019;60:1543-1544.
- 33. Da-ano R, Visvikis D, Hatt M. Harmonization strategies for multicenter radiomics investigations.

  Phys Med Biol. 2020;65:24TR02.
- 34. Da-ano R, Masson I, Lucia F, et al. Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies. *Sci Rep.* 2020;10:10248.
- 35. Orlhac F, Boughdad S, Philippe C, et al. A postreconstruction harmonization method for multicenter radiomic studies in PET. *J Nucl Med*. 2018;59:1321-1328.
- 36. Kolinger GD, Vállez García D, Kramer GM, et al. Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients. *EJNMMI Res.* 2019;9:1-12.
- 37. Kaalep A, Burggraaff CN, Pieplenbosch S, et al. Quantitative implications of the updated EARL 2019 PET-CT performance standards. *EJNMMI Phys.* 2019;6:1-16.
- 38. Lasnon C, Salomon T, Desmonts C, et al. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. *Ann Nucl Med*. 2017;31:125-134.
- 39. Nakajo M, Jinguji M, Aoki M, Tani A, Sato M, Yoshiura T. The clinical value of texture analysis of dual-time-point 18F-FDG-PET/CT imaging to differentiate between 18F-FDG-avid benign and malignant pulmonary lesions. *Eur Radiol*. 2020;30:1759-1769.
- 40. Chen S, Harmon S, Perk T, et al. Diagnostic classification of solitary pulmonary nodules using dual time 18 F-FDG PET/CT image texture features in granuloma-endemic regions. *Sci Rep.* 2017;7:1-8.


- 41. Noortman WA, Vriens D, Slump CH, et al. Adding the temporal domain to PET radiomic features.

  PLOS ONE. 2020;15:e0239438.
- 42. Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. *IEEE Trans Med Imaging*. 2006;25:907-921.
- 43. Armstrong IS, Kelly MD, Williams HA, Matthews JC. Impact of point spread function modelling and time of flight on FDG uptake measurements in lung lesions using alternative filtering strategies. *EJNMMI Phys.* 2014;1:1-18.
- 44. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging*. 2015;42:328-354.
- 45. Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity.


  \*Cancer Res. 2018;78:4786-4789.
- 46. Orlhac F, Soussan M, Chouahnia K, Martinod E, Buvat I. 18F-FDG PET-derived textural indices reflect tissue-specific uptake pattern in non-small cell lung cancer. *PLOS ONE*. 2015;10:e0145063.
- 47. Zwanenburg A, Vallières M, Abdalah MA, et al. The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping. *Radiology*. 2020;295:328-338.
- 48. LIFEx. Radiomic features. https://www.lifexsoft.org/index.php/resources/19-texture/radiomic-features. Accessed on December 21, 2020.

- 49. Lovat E, Siddique M, Goh V, Ferner RE, Cook GJR, Warbey VS. The effect of post-injection 18F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. *EJNMMI Res.* 2017;7:1-9.
- 50. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. *Lung Cancer*. 1995;2:883-887.
- 51. Boellaard R. Standards for PET image acquisition and quantitative data analysis. *J Nucl Med*. 2009;50:11S-20S.
- 52. Garcia-Vicente AM, Molina D, Pérez-Beteta J, et al. Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer. *Ann Nucl Med*. 2017;31:726-735.


# **Figures**




**Figure 1**: Flow chart for use-case classification of radiomic features. TRT: test-retest, ICC: intraclass correlation coefficient.



**Figure 2**: Effect of tracer uptake time on radiomic features. Left: distribution of Z-scores for each feature. Z-scores were calculated using the test-retest at 60 min post-injection scan as the baseline. Right: mean Z-score of each feature (dot indicates statistical significance). Analysis of images with reference settings.



**Figure 3**: Percentage of radiomic features with each use-case classification for each feature class. Classifications are: Cross-Sectional level 1 (CS1), Dual-Time-Point (DTP), Cross-Sectional level 2 (CS2), and Discarded. Analysis of images with reference settings.



**Figure 4**: Percentage of radiomic features with each use-case classification for each feature class in all image settings configurations. Columns of panels show different lesion delineation methods and rows show different image reconstructions and intensity discretization strategies. Classifications are: Cross-Sectional level 1 (CS1), Dual-Time-Point (DTP), Cross-Sectional level 2 (CS2), and Discarded. Analysis of images with reference settings are shown in the top left.